

## Mandarin Capital Partners Invests in TG Bio-pharma Dabbling in Pharmaceuticals Industry **Exclusive**

By PEdaily.cn

2

Updated: 2011-01-19 09:07:27

Mandarin Capital Partners has fulfilled the capital injection in TG Bio-pharma Co., Ltd. (TG Bio-pharma). This is the eighth project invested by Mandarin Capital Partners since its inception.

It was reported, the capital injection was jointly conducted by Mandarin Capital Partners and Euticals S.p.A, an Italian raw medicine producer.

Established in Jun. 2000, TG Bio-pharma, under the flag of Suzhou Tianma Pharma Group(Tianma Pharma), specializes in the production of normal raw medicines and polypeptide drugs(lyophilized preparation and particulate matter), emerging as the most competitive producers of cilindamycin phosphate, citicoline Sodium and enrofloxacin soluble powder in China and accounting for 40%-60% market share.

As the biggest Sino-European joint venture PE fund in the recorded history, Mandarin Capital Partners was initiated by China Development Bank, Export-import Bank of China and Intesa Sanpaolo S.p.A with a planned size of Euro328M.